Jeffrey Crawford, MD

Professor of Medicine
George Barth Geller Distinguished Professor of Immunology
Member of the Duke Cancer Institute
Campus mail 443 Seeley G. Mudd Bldg, Durham, NC 27710
Phone (919) 681-9509
Email address crawf006@mc.duke.edu

1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care

Accomplishments

1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.

In Their Words

Education and Training

  • M.D., Ohio State University, 1974

Publications

Smith, Thomas J., Kari Bohlke, Gary H. Lyman, Kenneth R. Carson, Jeffrey Crawford, Scott J. Cross, John M. Goldberg, et al. “Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.” J Clin Oncol 33, no. 28 (October 1, 2015): 3199–3212. https://doi.org/10.1200/JCO.2015.62.3488.

PMID
26169616
Full Text

Dunphy, Frank, John Yi, Mark Onaitis, Robyn Osborne, David Harpole, Jeffrey Crawford, Thomas D’Amico, Kent Weinhold, and Neal Ready. “Immunophenotyping of Circulating T Cells and TILs with Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer.” In Journal of Thoracic Oncology, 10:S356–57. ELSEVIER SCIENCE INC, 2015.

Scholars@Duke

Salama, Joseph K., Lin Gu, Xiaofei Wang, Jeffrey Bogart, Jeffrey Crawford, Steven Schild, Neal Ready, and Everett Vokes. “PCI Survival Improvement for Extensive Stage SCLC Limited to Patients on Maintenance Systemic Therapy: A Secondary Analysis of CALGB 30504.” Journal of Thoracic Oncology 10, no. 9 (September 1, 2015): S401–S401.

Scholars@Duke

Crawford, Jeffrey. “Cachexia.” In Journal of Thoracic Oncology, 10:S158–S158. ELSEVIER SCIENCE INC, 2015.

Scholars@Duke

Lyman, Gary H., David C. Dale, Jason C. Legg, Esteban Abella, Phuong Khanh Morrow, Sadie Whittaker, and Jeffrey Crawford. “Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?” Cancer Med 4, no. 8 (August 2015): 1153–60. https://doi.org/10.1002/cam4.454.

PMID
25810005
Full Text

Lyman, G. H., M. Reiner, P. K. Morrow, and J. Crawford. “The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy.” Ann Oncol 26, no. 7 (July 2015): 1452–58. https://doi.org/10.1093/annonc/mdv174.

PMID
25851633
Full Text

Ready, Neal E., Herbert H. Pang, Lin Gu, Gregory A. Otterson, Sachdev P. Thomas, Antonius A. Miller, Maria Baggstrom, et al. “Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).” J Clin Oncol 33, no. 15 (May 20, 2015): 1660–65. https://doi.org/10.1200/JCO.2014.57.3105.

PMID
25732163
Full Text

Pepek, Joseph M., Lawrence B. Marks, Mark F. Berry, Neal E. Ready, Nathan G. Gee, R Edward Coleman, Thomas A. D’Amico, Jeffrey Crawford, and Chris R. Kelsey. “Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy.” Pract Radiat Oncol 5, no. 2 (March 2015): 79–84. https://doi.org/10.1016/j.prro.2014.05.002.

PMID
25413417
Full Text

Havrilesky, Laura J., Maureen Reiner, Phuong Khanh Morrow, Holly Watson, and Jeffrey Crawford. “A review of relative dose intensity and survival in patients with metastatic solid tumors.” Crit Rev Oncol Hematol 93, no. 3 (March 2015): 203–10. https://doi.org/10.1016/j.critrevonc.2014.10.006.

PMID
25459671
Full Text

Culakova, Eva, Marek S. Poniewierski, Debra A. Wolff, David C. Dale, Jeffrey Crawford, and Gary H. Lyman. “The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study.” Springerplus 4 (2015): 396. https://doi.org/10.1186/s40064-015-1165-6.

PMID
26251780
Full Text

Pages